TST003

· Suzhou Transcenta Therapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TST003, covering 2025-12-17 to 2025-12-17. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors [Phase 1, Phase 2]